



A.Kay Mehra & Co.

CHARTERED ACCOUNTANTS

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

Limited Review Report for the quarter and period ended 30th September, 2019 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Raymed Labs Limited


We have reviewed the accompanying statement of unaudited standalone financial results of **Raymed Labs Limited** ("The Company") for the quarter ended 30th September, 2019, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting standard Specified under section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date : 12.11.2019

For A.Kay Mehra & Co.
Chartered Accountants
F.R.N.:050004C

CA Deepak Suneja
Partner
Membership No. 501957

UDIN- 19501957AAAMX22248

HEAD OFFICE : 120/128, LAJPAT NAGAR, KANPUR-208 005, PH. No. : 0512-2240909, 9956358976
BRANCH OFFICE : C-32, SECTOR-14, NOIDA-201301

Scanned by CamScanner

RAYMED LABS LIMITED
REGD. OFF: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304
Phone: 0120-2426900, 9412700300
E-mail: raymedlabs@rediffmail.com; Website: www.raymedlab.com,
CIN : L24111UP1992PLC014240

Statement of Unaudited Financial Results for the Period ended September 30, 2019

Particulars	Amt. (In Lacs.)					
	Quarter Ended			Half Year Ended		Year Ended
	3 Months ended on	Preceding 3 months ended on	Corresponding 3 months ended in the Previous Year	Year to Date Figures for Current Period Ende	Year to Date Figures for the Previous Year Ended	Previous Year Ended
	30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
	(Unaudited)					(Audited)
I. Revenue from Operations	0.00	0.00	0	0	0	0.00
II. Other Income	0.33	0.33	0.3	0.66	0.6	1.26
III. Total Income (I +II)	0.33	0.33	0.3	0.66	0.6	1.26
IV. Expenses						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.55	0.60	0.22	1.15	0.45	1.35
Depreciation and amortisation expenses	0.15	0.15	0.16	0.30	0.32	0.64
Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
Other Expenses	0.37	1.25	0.23	1.62	0.7	1.68
Total Expenses (IV)	1.07	2.00	0.61	3.07	1.47	3.66
V. Profit/(Loss) before exceptional items and tax (III- IV)	-0.74	-1.67	-0.31	-2.41	-0.87	-2.40
VI. Exceptional items	0.00	0.00	0.00	0.00	2.95	2.95
VII. Profit/(Loss) before tax (V-VI)	-0.74	-1.67	-0.31	-2.41	-3.82	-5.35
VIII. Tax Expense						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-0.74	-1.67	-0.31	-2.41	-3.82	-5.35
X. Profit/(Loss) from discontinued operations						
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-0.74	-1.67	-0.31	-2.41	-3.82	-5.35
XIV. Other Comprehensive Income						
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	-0.74	-1.67	-0.31	-2.41	-3.82	-5.35
XVI. Earnings per equity share (for continuing operation):						
(1) Basic	-0.017	-0.04	-0.007	-0.056	-0.089	-0.12
(2) Diluted	-0.017	-0.04	-0.007	-0.056	-0.089	-0.12
XVII. Earnings per equity share (for discontinued operation):						
(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVIII. Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	-0.017	-0.04	-0.007	-0.056	-0.089	-0.12
(2) Diluted	-0.017	-0.04	-0.007	-0.056	0.089	-0.12

Notes:

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 12th November, 2019. The Statutory Auditors have conducted a limited review of the above unaudited financial results and have expressed an unmodified report on the same.
- (2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- (3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- (5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

For RAYMED LABS LIMITED

(Ajai Goyal)
Wholetime Director
DIN : 02636418

Date: 12.11.2019
Place : Noida

RAYMED LABS LIMITED

REGD. OFF: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304

Phone: 0120-2426900, 9412700300

E-mail: raymedlabs@rediffmail.com; Website: www.raymedlab.com,

CIN : L24111UP1992PLC014240

Statement of Assets and Liabilities for the Half Year Ended on 30.09.2019

Particulars	Amount in (Lacs.)	
	As at Current Half Year Ended	As at Previous Year Ended
	30.09.2019	31.03.2019
	(Unaudited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	16.99	17.29
(b) Capital Work in Progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financials Assets-		
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other(to be specified)	0.00	0.00
(i) Deferred tax assets (net)	0.00	0
(j) Other non-current assets	0.00	0
Current Assets		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	2.49	2.49
(iii) Cash and cash equivalents	0.02	0.14
(iv) Bank Balance other than (iii) above	0.03	0.03
(v) Loans	6.10	6.10
(vi) Otheres (to be specified)	0.45	0.45
(c) Current tex Assets		
(d) Other current Assets		
TOTAL ASSETS	26.08	26.50
EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-622.60	-620.19

Liabilities		
Non -Current liabilities		
(a) Financials Liabilities	0.00	0.00
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities (other than specified in item (b) to be specified	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilites (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	200.59	199.85
(ii) Trade Payables	5.54	5.54
(iii) Other Financial liabilities (other than specified in item (c) to be specified	5	5.00
(b) Other current liabilities	10.20	8.95
(c) provisions	0.00	0.00
(d) Current Tax Liabilities	0.00	0.00
TOTAL EQUITY AND LIABILITES	26.08	26.50

For RAYMED LABS LIMITED

(Ajai Goyal)
Wholetime Director
DIN : 02636418

Date: 12.11.2019
Place : Noida

RAYMED LABS LIMITED

REGD. OFF: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304

Phone: 0120-2426900, 9412700300

E-mail: raymedlabs@rediffmail.com; Website: www.raymedlab.com,

CIN : L24111UP1992PLC014240

Statement of Cash Flows for the period ended September 30, 2019

Particulars	Amount in (Lacs.)	
	Quarter ended September 30, 2019 (01.07.2019- 30.09.2019)	Six months ended September 30, 2019 (01.04.2019- 30.09.2019)
Cash flow from Operating Activities		
Profit Before Tax	-0.74	-2.41
Adjustments for		
Depreciation and Amortisation Expense	0.15	0.30
Finance Costs	0	0
Interest Income on Fixed Deposits and Security Deposits measured at Amortised Cost	0	0
Dividend Income on Current Investments	0	0
Net (Gain) on Sale of Current Investments	0	0
Net Unrealised (Gain) / Loss on Foreign Currency Transactions and Translations	0	0
Share Based Payments	0	0
Fair Valuation (Gain)/ loss on Derivative Financial Instruments	0	0
Bad debts Written off	0	0
Allowances for Doubtful Trade Receivables (Expected Credit Loss Allowance)	0	0
Net loss on Disposal / Write off of Property, Plant, Equipment and Intangible Assets	0	0
Operating Profit Before Working Capital Changes	-0.59	-2.11
Changes in Working Capital		
Adjustments for (Increase) / Decrease in Operating Assets		
Loans to Employees	0	0
Security Deposits	0	0
Other Non-Current Assets	0	0
Trade Receivables	0	0
Other Financial Assets	0	0
Other Current Assets	0	0
Inventories	0	0
Adjustments for Increase / (Decrease) in Operating Liabilities		
Trade Payables	0	0
Other Financial Liabilities	0	0
Provisions	0	0

Other Current Liabilities	0.56	1.99
Cash Generated from Operations	0	0
Taxes Paid	0	0
Net Cash Generated from Operating Activities	0	0
Cash Flow from Investing Activities		
Payment for Purchase of Property, Plant, Equipment including Capital Work-in-Progress and Intangible Assets	0	0
Proceeds from Sale of Property, Plant, Equipment and Intangible Assets	0	0
Net Proceeds from Sale of Current Investments including investments under Scheme of Amalgamation	0	0
Interest Income Received	0	0
Dividend Income Received	0	0
Investment in Bank Deposits held as Margin Money	0	0
Net Cash Flow (Used in) Investing Activities		
Cash Flow from Financing Activities		
Proceeds from Issuance of Equity Shares	0	0
Securities Premium received	0	0
Proceeds from Current Borrowings	0	0
Repayment of Current Borrowings	0	0
Repayment of Non-Current Borrowings	0	0
Repayment of Lease Liabilities	0	0
Dividend and Dividend Distribution Tax Paid	0	0
Finance Costs Paid including Interest on Lease Liabilities	0	0
Net Cash Flow (Used in) Financing Activities	0	0
Net Increase / (Decrease) in Cash and Cash Equivalents	-0.03	-0.12
Cash and Cash Equivalents at beginning of the period	0.08	0.17
Changes in Cash and Cash Equivalents under Scheme of Amalgamation	0	0
Exchange Fluctuation Gain I (Loss) on Foreign Currency Bank Balances	0	0
Cash and Cash Equivalents at end of the period	0.05	0.05
Components of Cash and Cash Equivalents (At end of the period)		
Balances with Banks on Current Accounts	0.03	0.03
Cash on Hand	0.02	0.02
Notes		
<p>The above results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 12th November, 2019. The Statutory auditors have conducted a limited review of the above unaudited financial results and have expressed an unmodified report on the same.</p>		
For Raymed Labs Limited		
<p>Ajai Goyal Wholetime Director DIN: 02636418</p>		
<p>Date: 12.11.2019 Place: Noida</p>		